Abstract

In this project we will continue clinical trials of monoclonal antibodies in human lymphoma. We will focus on B cell lymphoma using custom-made anti-idiotype antibodies since this is the area in which the best results have so far been obtained. Refinements will be made in patient selection, antibody development and production and mode of antibody administration in order to take advantage of the information generated in our earlier trials and to improve the clinical results. The clinical and biological correlates of tumor response will be defined by studies on the antibodies, the tumor and the host. Each patient's tumor will be studied for genetic heterogeneity by immunoglobulin gene rearrangements and by multiple different anti-idiotype antibodies. In this way, we hope to continue to gain insights into the biology of human lymphoid malignancy.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA033399-04
Application #
3171292
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1982-07-01
Project End
1988-06-30
Budget Start
1985-07-01
Budget End
1986-06-30
Support Year
4
Fiscal Year
1985
Total Cost
Indirect Cost

  Institution

Name
Stanford University
Department
Type
Schools of Medicine
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305

  Publications

Kohrt, Holbrook E; Thielens, Ariane; Marabelle, Aurelien et al. (2014) Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123:678-86
Myklebust, June H; Irish, Jonathan M; Brody, Joshua et al. (2013) High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood 121:1367-76
Goldstein, Matthew J; Kohrt, Holbrook E; Houot, Roch et al. (2012) Adoptive cell therapy for lymphoma with CD4 T cells depleted of CD137-expressing regulatory T cells. Cancer Res 72:1239-47
Ai, Weiyun Z; Kohrt, Holbrook E K; Timmerman, John et al. (2011) Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma. Am J Hematol 86:515-8
Kohrt, Holbrook E; Houot, Roch; Goldstein, Matthew J et al. (2011) CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 117:2423-32
Younes, Sheren F; Beck, Andrew H; Ohgami, Robert S et al. (2011) The efficacy of HGAL and LMO2 in the separation of lymphomas derived from small B cells in nodal and extranodal sites, including the bone marrow. Am J Clin Pathol 135:697-708
Temmins, Caroline; Zhao, Shuchun; Lossos, Izidore S et al. (2011) HGAL protein expression persists in disorders of germinal center dissolution: potential role of HGAL in the germinal center microenvironment. Appl Immunohistochem Mol Morphol 19:266-72
Goldstein, Matthew J; Varghese, Bindu; Brody, Joshua D et al. (2011) A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood 117:118-27
Irish, Jonathan M; Myklebust, June H; Alizadeh, Ash A et al. (2010) B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A 107:12747-54
Nicodemus, Christopher F; Wang, Lin; Lucas, Julie et al. (2010) Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy. Am J Obstet Gynecol 202:608.e1-8

Showing the most recent 10 out of 146 publications